MARF registers a €25 million bond programme by ATRYS HEALTH on its debut on this market

  • With this Programme the company opens a new access to capital markets in order to finance its future CAPEX investments
  • The Programme will allow to launch during the next 12 months, in a flexible way and according to its financial needs, different bonds tranches

MARF, BME’s Fixed Income market, today registered a 25 million euro new bond programme by Atrys Health, which taps this market for the first time to raise funding. Through this programme the company opens up a new access route to the capital markets to finance its future investments in CAPEX, with the opening of new high precision radiotherapy centers, and inorganic growth operations.

The programme will allow the company to launch different tranches of bond issues over the next 12 months, in a flexible manner and based on its needs. The securities issued will have a nominal unit value of 100,000 euros and will be geared to qualified investors.

EBN Banco acts as the Bond Programme’s Sole-Arranger and Bookrunner, while Norgestion will be the Registered Advisor of ATRYS in MARF. The firm Pinsent Masons Spain has provided legal advice to the issuer for the opening of this new issuance mechanism while Gómez-Acebo & Pombo Abogados has advised the Placement Entity.

Atrys is mainly concerned with the provision of diagnostic services and top-level oncological medical treatments, aimed to provide patients with individualised therapy, as well as the development of new therapeutic modalities and diagnostic tools. The company has several laboratories, equipped with the necessary material and technology for diagnosis and research, located in Barcelona and Granada.

Including the acquisitions made last year, Atrys Health obtained total revenues of 11.08 million euros in 2018 and an EBITDA of 3.32 million. The company has been listed on the MAB since July 2016.